Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG versus NOVOLOG MIX 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG versus NOVOLOG MIX 50 50.
NOVOLOG vs NOVOLOG MIX 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that lowers blood glucose by binding to insulin receptors, enhancing peripheral glucose uptake, and inhibiting hepatic glucose production.
Insulin analog with rapid onset of action due to substitution of amino acid proline with aspartic acid at position B28, facilitating faster dissociation from hexamers into monomers after subcutaneous injection. Biphasic formulation containing 50% insulin aspart protamine (intermediate-acting) and 50% insulin aspart (rapid-acting).
Subcutaneous injection: 0.5-1 unit/kg/day divided into 3 or more doses given within 15 minutes before or after meals. Typical total daily dose range 0.5-1.5 units/kg.
Subcutaneous injection. Typical adult dose: 0.5 to 1 unit/kg/day divided into two injections (with breakfast and dinner). Dose is individualized based on blood glucose levels and patient needs.
None Documented
None Documented
Terminal elimination half-life is 1.2-1.5 hours in healthy individuals, reflecting rapid clearance. In renal impairment (e.g., eGFR <30 mL/min), half-life may be prolonged up to 2-3 hours due to reduced degradation.
6-8 hours (terminal half-life of protamine-bound fraction; free insulin component half-life ~4-5 minutes).
Renal excretion accounts for approximately 60-80% of insulin aspart degradation products; unchanged drug is minimally excreted. Biliary/fecal excretion is negligible (<10%).
Renal: 50-60% as intact insulin, 30-40% as metabolites; biliary/fecal: minimal (<1%).
Category C
Category C
Insulin Analog
Insulin Analog